MCID: ESP002
MIFTS: 49

Esophageal Varix

Categories: Cardiovascular diseases, Gastrointestinal diseases, Rare diseases

Aliases & Classifications for Esophageal Varix

MalaCards integrated aliases for Esophageal Varix:

Name: Esophageal Varix 12 29 15
Esophageal Varices 12 75 53 55 15 17
Bleeding Esophageal Varices 12 55 72
Esophageal Varices in Disease Classified Elsewhere, with Bleeding 12
Esophageal Varices with Bleeding in Disease Ec 12
Esophageal Varices Without Mention of Bleeding 12
Esophageal Varices Without Bleeding 12
Esophageal Varices with Bleeding 12
Bleeding Oesophageal Varices 12

Classifications:



External Ids:

Disease Ontology 12 DOID:112
ICD9CM 35 456.0 456.2 456.20
NCIt 50 C78282
SNOMED-CT 68 17709002
ICD10 33 I85.01
UMLS 72 C0155789 C0155791 C0155792

Summaries for Esophageal Varix

MalaCards based summary : Esophageal Varix, also known as esophageal varices, is related to hypersplenism and portal vein thrombosis. An important gene associated with Esophageal Varix is SST (Somatostatin), and among its related pathways/superpathways is FOXA2 and FOXA3 transcription factor networks. The drugs Nadolol and Simvastatin have been mentioned in the context of this disorder. Affiliated tissues include liver, spleen and testes, and related phenotypes are Strongly decreased CFP-tsO45G cell surface transport and digestive/alimentary

Wikipedia : 75 Esophageal varices are extremely dilated sub-mucosal veins in the lower third of the esophagus. They are... more...

Related Diseases for Esophageal Varix

Diseases related to Esophageal Varix via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 347)
# Related Disease Score Top Affiliating Genes
1 hypersplenism 31.2 F2 ALB
2 portal vein thrombosis 31.1 F2 AFP
3 cholangitis 30.8 GPT F2 ALB
4 acute liver failure 30.7 GPT F2 ALB
5 hepatorenal syndrome 30.6 F2 ALB
6 alcoholic liver cirrhosis 30.6 F2 ALB AFP
7 hernia, hiatus 30.6 ATP4A ATP12A
8 peliosis hepatis 30.5 F2 AFP
9 bilirubin metabolic disorder 30.4 GPT F2 ALB
10 aspiration pneumonitis 30.4 ATP4A ATP12A
11 duodenitis 30.4 ATP4A ATP12A
12 alcoholic hepatitis 30.4 GPT F2 ALB
13 peptic esophagitis 30.4 ATP4A ATP12A
14 hepatic coma 30.4 GPT F2 ALB
15 hepatic encephalopathy 30.3 GPT F2 ALB
16 obstructive jaundice 30.2 GPT F2 ALB
17 esophageal candidiasis 30.2 ATP4A ATP12A
18 dyskinesia of esophagus 30.2 ATP4A ATP12A
19 bile reflux 30.2 ATP4A ATP12A
20 active peptic ulcer disease 30.1 F2 ATP4A ATP12A
21 portal hypertension 30.0 SST GPT F2 DGUOK ALB
22 aspiration pneumonia 30.0 ATP4A ATP12A ALB
23 hepatitis b 30.0 GPT F2 ALB AFP
24 esophageal disease 30.0 ATP4A ATP12A ALB
25 liver disease 30.0 GPT F2 ALB AFP
26 microinvasive gastric cancer 30.0 ATP4A ATP12A
27 liver cirrhosis 29.9 SST GPT F2 ALB AFP
28 viral hepatitis 29.9 GPT F2 ALB AFP
29 nodular regenerative hyperplasia 11.9
30 fatty liver disease 11.7
31 cerebroretinal microangiopathy with calcifications and cysts 2 11.4
32 non-a-e hepatitis 10.6 F2 ALB
33 antipyrine metabolism 10.6 F2 ALB
34 epstein-barr virus hepatitis 10.6 F2 ALB
35 fournier gangrene 10.6 F2 ALB
36 yellow nail syndrome 10.6 SST ALB
37 abdominal tuberculosis 10.6 F2 ALB
38 hepatoportal sclerosis 10.6 GPT F2
39 chylothorax, congenital 10.6 SST ALB
40 varicose veins 10.5
41 splenic disease 10.5 F2 ALB
42 endometrial small cell carcinoma 10.5 F2 AFP
43 ascending cholangitis 10.5 F2 ALB
44 pancreatoblastoma 10.5 SST AFP
45 hepatitis d 10.5 GPT F2
46 hepatitis c virus 10.5
47 hepatoid adenocarcinoma 10.5 ALB AFP
48 compartment syndrome 10.4 F2 ALB
49 fascioliasis 10.4 GPT ALB
50 opisthorchiasis 10.4 GPT AFP

Comorbidity relations with Esophageal Varix via Phenotypic Disease Network (PDN):


Active Peptic Ulcer Disease Acute Cystitis
Alcoholic Liver Cirrhosis Deficiency Anemia
Esophageal Disease Esophagitis
Heart Disease Hepatic Encephalopathy
Portal Hypertension

Graphical network of the top 20 diseases related to Esophageal Varix:



Diseases related to Esophageal Varix

Symptoms & Phenotypes for Esophageal Varix

GenomeRNAi Phenotypes related to Esophageal Varix according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Strongly decreased CFP-tsO45G cell surface transport GR00360-A-2 8.92 DGUOK GPT JMJD6 SST

MGI Mouse Phenotypes related to Esophageal Varix:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 9.43 ALB ATP12A ATP4A F2 JMJD6 SST
2 homeostasis/metabolism MP:0005376 9.28 AFP ALB ATP12A ATP4A EOGT F2

Drugs & Therapeutics for Esophageal Varix

Drugs for Esophageal Varix (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 153)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Nadolol Approved Phase 4 42200-33-9 39147
2
Simvastatin Approved Phase 4 79902-63-9 54454
3
Prazosin Approved Phase 4 19216-56-9 4893
4
Ethanolamine oleate Approved Phase 4 2272-11-9
5
Carvedilol Approved, Investigational Phase 4 72956-09-3 2585
6
Nitric Oxide Approved Phase 4 10102-43-9 145068
7
Isosorbide Dinitrate Approved, Investigational Phase 4 87-33-2 6883
8
AT-101 Approved, Investigational Phase 4 90141-22-3, 652-67-5 12597
9
Somatostatin Approved, Investigational Phase 4 38916-34-6, 51110-01-1 53481605
10
Terlipressin Approved, Investigational Phase 4 14636-12-5 72081
11
Heparin Approved, Investigational Phase 4 9005-49-6 46507594 772
12
Warfarin Approved Phase 4 81-81-2 6691 54678486
13
Pantoprazole Approved Phase 4 102625-70-7 4679
14
Thrombin Approved, Investigational Phase 4
15
Acenocoumarol Approved, Investigational Phase 4 152-72-7 9052 54676537
16
Phylloquinone Approved, Investigational Phase 4 84-80-0
17
Dalteparin Approved Phase 4 9005-49-6
18 Bemiparin Approved, Investigational Phase 4 91449-79-5
19
Octreotide Approved, Investigational Phase 4 83150-76-9 383414 6400441
20
Propranolol Approved, Investigational Phase 4 525-66-6 4946
21
Tranexamic Acid Approved Phase 4 1197-18-8 5526
22
Calcium Approved, Nutraceutical Phase 4 7440-70-2 271
23
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4 22737-96-8, 11103-57-4, 68-26-8 9904001 445354
24
Menadione Approved, Nutraceutical Phase 4 58-27-5 4055
25 Menaquinone Investigational Phase 4 1182-68-9
26 Lipid Regulating Agents Phase 4
27 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 4
28 Hypolipidemic Agents Phase 4
29 Anticholesteremic Agents Phase 4
30 Antimetabolites Phase 4
31 Pharmaceutical Solutions Phase 4
32 Sclerosing Solutions Phase 4
33 Nitric Oxide Donors Phase 4
34 Hormones Phase 4
35 diuretics Phase 4
36 Antioxidants Phase 4
37 Adrenergic alpha-Antagonists Phase 4
38 Natriuretic Agents Phase 4
39 Adrenergic alpha-1 Receptor Antagonists Phase 4
40 isosorbide-5-mononitrate Phase 4
41 Protective Agents Phase 4
42 Sympatholytics Phase 4
43 calcium channel blockers Phase 4
44 Autonomic Agents Phase 4
45 Calcium, Dietary Phase 4
46 Hormone Antagonists Phase 4
47 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4
48 retinol Phase 4
49 Retinol palmitate Phase 4
50 Anticoagulants Phase 4

Interventional clinical trials:

(show top 50) (show all 141)
# Name Status NCT ID Phase Drugs
1 Endoscopic Treatment Versus Propranolol for Primary Prevention of Patients With Hepatocellular Carcinoma and Concomitant Esophageal Varices Unknown status NCT01970748 Phase 4 Propranolol
2 Banding Ligation Plus Propranolol Versus Banding Ligation to Prevent Rebleeding of Esophageal Varices Unknown status NCT02740166 Phase 4 propranolol
3 The Impact of Early Feeding Following Ligation of the Acute Bleeding Varices Unknown status NCT01287702 Phase 4
4 Randomized and Controlled Study of Endoscopic Ligation, Nadolol and Isosorbide Mononitrate vs Endoscopic Ligation and Nadolol Alone, or Associated With Isosorbide Mononitrate or Prazosin, Depending of the Hemodinamyc Response Unknown status NCT00563602 Phase 4
5 Endoscopic Treatment Alone Versus Combined Propranolol and Endoscopic Treatment of Acute Variceal Hemorrhage in Patients With Hepatocellular Carcinoma Unknown status NCT01451658 Phase 4 propranolol
6 Prevention of Progression of Portal Hypertension in Compensated Cirrhosis Using Selective Hepatic Vasodilators. A Double-blind, Multicenter,Randomized Controlled Trial Unknown status NCT01282398 Phase 4 Simvastatin;placebo
7 Prevention of Esophageal Variceal Rebleeding Unknown status NCT00863837 Phase 4 terlipressin (vasoconstrictor);pantoloc (proton pump inhibitor)
8 A Randomized Trial of GVS Alone vs. Nadolol Unknown status NCT01298271 Phase 4 propranolol
9 A Randomized Tril of Endoscopic Cyanoacrylate Obliteration vs. Nadolol Unknown status NCT00567216 Phase 4 Nadolol
10 A Controlled Trial of Nadolol Plus Isosorbide Mononitrate vs. Carvedilol for the Prevention of Variceal Rebleeding Completed NCT01103154 Phase 4 carvedilol;nadolol + ISMN
11 A Randomized, Controlled Trial of Ligation Plus Nadolol Versus Nadolol Alone in the Prophylaxis of First Variceal Bleeding in Cirrhosis Completed NCT00921349 Phase 4 Nadolol
12 Efficacy And Safety Of Terlipressin Vs Octreotide As Adjuvant Therapy In Bleeding Esophageal Varices Completed NCT00534677 Phase 4 Terlipressin;Octreotide
13 Endoscopic Treatment of Esophageal Varices in Advanced Liver Disease Patients: a Randomized Controlled Trial Comparing Band Ligation and Cyanoacrylate Injection Completed NCT00799851 Phase 4 cyanoacrylate injection
14 Hemodynamic Effects of Terlipressin and High Dose Octreotide on Patients With Liver Cirrhosis Related Esophageal Varices: A Randomized, Placebo-controlled Multicenter Trial Completed NCT02119884 Phase 4 Terlipressin;Octreotide
15 Appropriate Time Interval for Repeat Sessions of Endoscopic Ligation for the Eradication of Esophageal Varices Completed NCT01291277 Phase 4
16 A Randomized, Controlled, Multicentric Trial Comparing Endoscopic Band Ligation Versus Ransjugular Intrahepatic Portosystemic Stent Shunt in Cirrhotic Patients With Recurrent Variceal Bleeding Non Responding to Medical Therapy Completed NCT00570973 Phase 4
17 Randomized Double Blind Dummy Controlled Trial Of 24 Versus 72 Hours Of Terlipressin As An Adjuvant Therapy In Acute Variceal Bleed Completed NCT00369694 Phase 4 Terlipressin;Terlipressin & then Dummy
18 Comparison of Endoscopic Injection of Conventional and Double Doses Cyanoacrylate for Gastric Variceal Hemorrhage Completed NCT00735358 Phase 4
19 PROPRANOLOL ASSOCIATED WITH ENDOSCOPIC BAND LIGATION REDUCES RECURRENCE OF ESOPHAGEAL VARICES FOR PRIMARY PROPHYLAXIS OF VARICEAL BLEEDING?: A RANDOMIZED CONTROLLED TRIAL Completed NCT01893541 Phase 4 PROPRANOLOL
20 A Randomized, Controlled Trial of Ligation Plus Vasoconstrictor vs.Ligation Plus Proton Pump Inhibitor in the Control of Acute Esophageal Variceal Bleeding Completed NCT01112852 Phase 4 pantoloc 40 mg;somatostatin or terlipressin
21 A Clinical Trial of the Vessel Sealing System (LigaSure) in Azygoportal Disconnection and Splenectomy in Patients With Portal Hypertension Completed NCT00965744 Phase 4
22 Carvedilol Plus Endoscopic Cyanoacrylate Injection Versus Endoscopic Cyanoacrylate Injection for Secondary Prophylaxis of Gastric Variceal Bleeding Completed NCT02504723 Phase 4 carvedilol;cyanoacrylate
23 Short-course Somatostatin Versus Terlipressin Infusion in Combination With Endoscopic Variceal Ligation for the Prevention of Early Esophageal Variceal Rebleeding Completed NCT02757703 Phase 4 Somatostatin;Terlipressin;Pantoprazole
24 Randomized Controlled Trial to Compare Treatment With Oral Anticoagulation With Antagonists of vitaminK vs Low Molecular Weight Heparin(Bemiparin) in Patients With Anticoagulation Criteria and an Episode of Gastrointestinal Bleeding. Completed NCT01727453 Phase 4 warfarin;Bemiparina
25 Comparison of 24-hours Versus 72-hours of Octreotide Infusion Along With Endoscopic Therapy in Preventing Early Rebleed From Esophageal Varices: a Multi-center, Randomized Clinical Study Recruiting NCT03624517 Phase 4 Octreotide
26 RCT Comparing the Efficacies of Endoscopic Band Ligation (EBL) and Combined Treatment of Beta-blocker and EBL for the Prevention of Esophageal Variceal Rebleeding in Patients With Previous Endoscopic Variceal Treatment Recruiting NCT00966082 Phase 4
27 Efficacy and Safety of Early Administration of Tranexamic Acid in Cirrhotic Patients Presenting With Acute Upper Gastrointestinal Bleeding: a Multicenter, Randomized, Double Blind, Placebo-controlled Trial (Modified by amendment1) Recruiting NCT03023189 Phase 4 Tranexamic acid;Placebo
28 A Controlled Trial of Ligation Plus Drug Vs. Drug Alone in the Prevention of Variceal Rebleeding Terminated NCT00371943 Phase 4
29 A Multi-center Randomized Controlled Study of Primary Prevention of Esophageal Variceal Bleeding in Cirrhotic Patients Treated With HVPG-guided Beta- Blocker Therapy or Standard Heart Rate-guided Beta-blocker Therapy Unknown status NCT01618890 Phase 3
30 Effect of Administration "Add on" of Rifaximin on Portal Hypertension of Patients With Liver Cirrhosis and Esophageal Varices in Standard Therapy With Propranolol Unknown status NCT02508623 Phase 3 Rifaximin;Placebo
31 Hemodynamic Response of Rifaximin and Non-selective β-blocker Combination Therapy Versus Non-selective β-blocker Monotherapy in Cirrhotic Patients With Esophageal Varices Unknown status NCT01897051 Phase 2, Phase 3 Rifaximin + propranolol;Propranolol + Placebo
32 COMPARATIVE STUDY OF NORFLOXACIN AND PROBIOTICS ON PORTAL PRESSURE IN PATIENTS WITH CIRRHOSIS AND LARGE VARICES WHO HAVE NEVER BLED IN THE PAST Unknown status NCT01134692 Phase 3 Propranolol, Norfloxacin, VSL#3
33 To Study the Effect of Nonselective Beta Blockers in Advanced Stage Liver Disease With Ascites Unknown status NCT02649335 Phase 3 Propranolol
34 Autologous Bone Marrow Stem Cells Infusion Through Hepatic Artery in Open Abdominal Portal Hypertension Surgery for the Treatment of Liver Cirrhosis: a Prospective, Non-randomized, Controlled Study Unknown status NCT01560845 Phase 2, Phase 3
35 Prospective Randomized Study on the Efficacy of Endoscopic Injection Therapy With Fibrin Sealant Versus Endoscopic Ligature for Acute Hemostasis and the Prophylaxis of Recurrent Bleeding From Esophageal Varices Completed NCT00161915 Phase 3 Fibrin Sealant
36 Control of Acute Variceal Bleeding Using the Multi-shooter Band Ligator Compared to Injection Sclerotherapy. Completed NCT01131962 Phase 3
37 Danish Carvedilol Study in Portal Hypertension. Carvedilol in the Prevention of Bleeding in Portal Hypertension and Esophageal Varices Completed NCT00493480 Phase 3 carvedilol;propranolol
38 Simvastatin Effect in Portal Hypertension Measured by Portal Hemodynamic Gradient and Azygos Vein Doppler in Echoendoscopy Completed NCT02134626 Phase 3 Simvastatin;Placebo pill
39 Randomized, Double-Blind Study of Timolol (A Nonselective Beta-Adrenergic Blocker) vs Placebo to Prevent Complications of Hepatic Portal Hypertension in Patients With Cirrhosis Completed NCT00006398 Phase 3 Timolol Maleate;Placebo
40 Comparison of Endoscopic Variceal Ligation (EVL) and Propranolol in Secondary Prophylaxis of Variceal Bleeding in Patients With Non Cirrhotic Portal Hypertension (NCPH): A Prospective Randomized Controlled Trial Completed NCT01000779 Phase 3 Propranolol
41 The Early Use of Sanvar® With Endoscopic Treatment for the Control of Acute Variceal Bleeding Due to Portal Hypertension Completed NCT00331188 Phase 3 Sanvar® (vapreotide)
42 Hepatocellular Carcinoma Postoperative Adjuvant Therapy Disease Committee of Taiwan Cooperative Oncology Group Completed NCT00149565 Phase 3 IFN-α2b
43 Diclophenac Versus Placebo for Pain Control in Diagnostic Colonoscopy: a Randomized Controlled Study Completed NCT02339428 Phase 3 diclophenac sodium;Placebo
44 Esophageal Stent is More Effective Than Tamponade Controlling Refractory Esophageal Variceal Bleeding: a Randomized Controlled Trial Completed NCT01242280 Phase 3
45 Scleroligation is a Safe and Effective New Technique for Eradication of Gastroesophageal Varices. Recruiting NCT02646202 Phase 3
46 Apixaban for Intrahepatic Non Cirrhotic Portal Hypertension Recruiting NCT04007289 Phase 3 Apixaban;Placebo
47 Endoscopic Injection Sclerotherapy Versus N-butyl-2-cyanoacrylate Injection in the Management of Actively Bleeding Esophageal Varices Active, not recruiting NCT03388125 Phase 3 Injection Sclerotherapy;N-butyl-2-cyanoacrylate
48 Beta Blockers Versus Variceal Band Ligation and Beta Blockers for Primary Prophylaxis of Variceal Bleeding Terminated NCT00409084 Phase 3
49 A New Technique to Enhance Detection of Small Esophageal Varices by PillCam ESO Capsule Endoscopy Withdrawn NCT00911131 Phase 3
50 A Phase 3 Study of Carvedilol vs Variceal Band Ligation vs Combination Therapy for Primary Prophylaxis of Variceal Bleeding Withdrawn NCT02066649 Phase 3 Carvedilol

Search NIH Clinical Center for Esophageal Varix

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Ethanolamine oleate

Genetic Tests for Esophageal Varix

Genetic tests related to Esophageal Varix:

# Genetic test Affiliating Genes
1 Esophageal Varix 29

Anatomical Context for Esophageal Varix

MalaCards organs/tissues related to Esophageal Varix:

41
Liver, Spleen, Testes, Colon, Kidney, Heart, Brain

Publications for Esophageal Varix

Articles related to Esophageal Varix:

(show top 50) (show all 6219)
# Title Authors PMID Year
1
Comparison of liver biopsy and transient elastography based on clinical relevance. 9 38
18818788 2008
2
[Splanchnic hemodynamic effects of somatostatin and octreotide in cirrhotic patients. A Doppler ultrasonographic study]. 9 38
19025306 2008
3
Right liver lobe/albumin ratio: contribution to non-invasive assessment of portal hypertension. 9 38
17879402 2007
4
[Non-endoscopic predictors of large esophageal varices in patients with liver cirrhosis]. 9 38
17641556 2007
5
Coagulation abnormalities in cirrhotic patients with portal vein thrombosis. 9 38
18257465 2007
6
[Bleeding oesophageal varices--therapeutic options]. 9 38
17633875 2007
7
[The value of Doppler-ultrasonography and laboratory tests as non-invasive predictors of the presence of esophageal varices in patients with chronic liver disease]. 9 38
17047433 2006
8
[Non-invasive diagnosis of portal hypertension in cirrhosis. Application to the primary prevention of varices]. 9 38
16435503 2005
9
Review: somatostatin and its analogues do not reduce mortality in acute bleeding esophageal varices. 9 38
15989304 2005
10
Earlier recurrence of esophageal varices, following therapy, in patients with primary biliary cirrhosis (PBC) compared with non-PBC patients. 9 38
15580402 2004
11
Prevalence and predictors of esophageal varices in patients with primary sclerosing cholangitis. 9 38
14752839 2004
12
Two findings of portal hypertension: evaluation of correlation between serum-ascites albumin gradient and esophageal varices in non-alcoholic cirrhosis. 9 38
15048594 2003
13
[Vasoconstrictive Therapies for Bleeding Esophageal Varices and their Mechanisms of Action]. 9 38
14562199 2003
14
Review: Somatostatin analogues reduce blood products used in acute bleeding esophageal varices but do not reduce mortality. 9 38
12418833 2002
15
Prognosis of hepatocellular carcinoma associated with Child class B and C cirrhosis in relation to treatment: a multivariate analysis of 411 patients at a single center. 9 38
12483269 2002
16
Risk factors for infections in cirrhotic patients with and without hepatocellular carcinoma. 9 38
12522534 2002
17
Prognostic factors for survival in patients with compensated cirrhosis and small hepatocellular carcinoma after percutaneous ethanol injection therapy. 9 38
11443618 2001
18
Which patients with cirrhosis should undergo endoscopic screening for esophageal varices detection? 9 38
11172334 2001
19
[Drug therapy of hemorrhage in esophageal and gastric varices: role of vasoactive drugs]. 9 38
11291271 2000
20
Surgical indications for advanced hepatocellular carcinoma. 9 38
11020886 2000
21
[Sclerotherapy versus somatostatin in the treatment of upper digestive hemorrhage caused by rupture of esophageal varices]. 9 38
11236267 2000
22
Non-invasive diagnosis of esophageal varices in chronic liver diseases. 9 38
10580584 1999
23
Resource analysis of somatostatin in the treatment of bleeding esophageal varices. 9 38
10567787 1999
24
Somatostatin or octreotide in acute variceal bleeding. 9 38
10207229 1999
25
Benefit of prophylactic endoscopic sclerotherapy of esophageal varices. A retrospective analysis. 9 38
9602001 1998
26
Approach to the management of bleeding esophageal varices: role of somatostatin. 9 38
9603441 1998
27
[Gastroenterology. I: General gastroenterology]. 9 38
9499375 1997
28
Cirrhosis: a new, but expected cause of biliary sludge. 9 38
9046383 1997
29
[Molecular biology, pharmacology and signal transduction of 5 cloned human somatostatin receptors]. 9 38
9045539 1996
30
Terlipressin (glypressin) versus somatostatin in the treatment of bleeding esophageal varices--final report of a placebo-controlled, double-blind study. 9 38
8921578 1996
31
Prognostic value of the galactose test in predicting survival of patients with cirrhosis evaluated for liver transplantation. A prospective multicenter Italian study. AISF Group for the Study of Liver Transplantation. Associazione Italiana per lo Studio del Fegato. 9 38
8912146 1996
32
Survival in alcoholic liver cirrhosis: prognostic value of portal pressure, size of esophageal varices and biochemical data. Comparison with Child classification. 9 38
8776835 1996
33
Hepatic resection of hepatocellular carcinoma in cirrhotic livers: is it unjustified in impaired liver function? 9 38
8693420 1996
34
Predictive score for the development of hepatocellular carcinoma and additional value of liver large cell dysplasia in Western patients with cirrhosis. 9 38
8621142 1996
35
[Randomized trial and meta-analysis of somatostatin versus placebo in bleeding esophageal varices]. 9 38
8685994 1996
36
[Drug therapy of acute esophageal varices bleeding (vasopressin, terlipressin, somatostatin)]. 9 38
8571017 1995
37
A meta-analysis of somatostatin versus vasopressin in the management of acute esophageal variceal hemorrhage. 9 38
7557097 1995
38
Is somatostatin effective in the treatment of acute bleeding caused by esophageal varices? 9 38
7919564 1994
39
[Terlipressin and somatostatin in the treatment of hemorrhages from rupture of esophageal varices]. 9 38
7958662 1994
40
Albumin inhibits hemolysis of erythrocytes induced by ethanolamine oleate during endoscopic injection sclerotherapy. 9 38
8462932 1993
41
[Effectiveness of endoscopic sclerotherapy in the treatment of bleeding esophageal varices]. 9 38
8465042 1993
42
Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver. 9 38
1426884 1992
43
Terlipressin vs. somatostatin in bleeding esophageal varices: a controlled, double-blind study. 9 38
1350562 1992
44
Somatostatin versus Sengstaken balloon tamponade for primary haemostasia of bleeding esophageal varices. A randomized pilot study. 9 38
1672539 1991
45
Randomized, double-blind, placebo-controlled trial of somatostatin for variceal bleeding. Emergency control and prevention of early variceal rebleeding. 9 38
1976563 1990
46
[Drug treatment of acute esophageal varices hemorrhage using vasoactive substances (somatostatin and octreotide)]. 9 38
1980776 1990
47
Comparison of somatostatin and vasopressin in bleeding esophageal varices. 9 38
1973591 1990
48
Factors of prognostic importance in primary biliary cirrhosis. 9 38
2305209 1990
49
Role of Spleen Stiffness Measurement by 2D-Shear Wave Elastography in Ruling Out the Presence of High-Risk Varices in Cirrhotic Patients. 38
30989464 2019
50
The current knowledge about the therapeutic use of endoscopic sclerotherapy and endoscopic tissue adhesives in variceal bleeding. 38
31389265 2019

Variations for Esophageal Varix

Expression for Esophageal Varix

Search GEO for disease gene expression data for Esophageal Varix.

Pathways for Esophageal Varix

Pathways related to Esophageal Varix according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 10.44 F2 ALB AFP

GO Terms for Esophageal Varix

Cellular components related to Esophageal Varix according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.43 SST GPT F2 ATP4A ALB AFP
2 endoplasmic reticulum lumen GO:0005788 8.92 F2 EOGT ALB AFP

Biological processes related to Esophageal Varix according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell surface receptor signaling pathway GO:0007166 9.63 SST JMJD6 F2
2 cellular protein metabolic process GO:0044267 9.58 F2 ALB AFP
3 potassium ion import across plasma membrane GO:1990573 9.43 ATP4A ATP12A
4 ATP hydrolysis coupled proton transport GO:0015991 9.37 ATP4A ATP12A
5 apoptotic cell clearance GO:0043277 9.32 LRP1 JMJD6
6 cellular sodium ion homeostasis GO:0006883 9.26 ATP4A ATP12A
7 establishment or maintenance of transmembrane electrochemical gradient GO:0010248 9.16 ATP4A ATP12A
8 sodium ion export across plasma membrane GO:0036376 8.96 ATP4A ATP12A
9 cellular potassium ion homeostasis GO:0030007 8.62 ATP4A ATP12A

Molecular functions related to Esophageal Varix according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 sodium:potassium-exchanging ATPase activity GO:0005391 8.96 ATP4A ATP12A
2 potassium:proton exchanging ATPase activity GO:0008900 8.62 ATP4A ATP12A

Sources for Esophageal Varix

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....